Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Summary

Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are 2:107,510,000-107,540,000 polymorphism non-carriers with the primary objective to compare the effect of piromelatine to that of placebo on the AD Assessment Scale cognitive subscale (ADAS-cog14) at Week 26 of double-blind treatment.

Timeline

Start

2022-05-12

Primary completion

2025-06

Completion

2025-06

Publications

• Hagel JM, Chang L, Li J, Chen X, Yu L, Gallant JA, Facchini PJ. Bioproduction of a Large-Scale Library of Tryptamine Derivatives for Neuropsychiatric Drug Screening. ACS Chem Biol. 2025 Jun 20;20(6):1212-1231. doi: 10.1021/acschembio.4c00857. Epub 2025 May 15.

Drugs

Indications